A Glioma-Derived Analog to Platelet-Derived Growth Factor: Demonstration of Receptor Competing Activity and Immunological Crossreactivity

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 81; no. 3; pp. 926 - 930
• Main Authors: Nister, Monica, Heldin, Carl-Henrik, Wasteson, Ake, Westermark, Bengt
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences of the United States of America 01.02.1984; National Acad Sciences
• Subjects: Antibodies; Binding, Competitive; Cell growth; Cell lines; Cells, Cultured; Cultured cells; Electrophoresis; Fibroblasts; Glioma; Glioma - metabolism; glioma cells; Humans; Immunology; immunoprecipitation; Kinetics; Male; man; platelet-derived growth factor; Platelet-Derived Growth Factor - metabolism; Radioimmunoassay; Receptors; Receptors, Cell Surface - metabolism; Receptors, Platelet-Derived Growth Factor; Skin - metabolism; Washing
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.81.3.926

A human clonal glioma cell line, U-343 MGa Cl 2, cultured under serum-free conditions, was found to release a factor that competed with125I-labeled platelet-derived growth factor (125I-PDGF) for binding to human foreskin fibroblasts. The concentration of competing activity in conditioned medium was equal to 20-30 ng of PDGF per ml. The PDGF receptor competing activity had an elution position on Sephadex G-200 close to that of tracer PDGF. The same fractions in the chromatogram also contained growth-promoting activity and material active in a PDGF radioimmunoassay. Incubation of partially purified, (125I-labeled glioma factor with fibroblasts, or a rabbit anti-PDGF serum, led to the selective binding of a component with an estimated Mrof 31,000, as shown by NaDodSO4/gel electrophoresis under nonreducing conditions. After reduction this component migrated as a Mr18,000 protein. Thus, the behavior in NaDodSO4/gel electrophoresis was similar to that of PDGF. Furthermore, incubation of partially purified glioma factor with immobilized PDGF antibodies markedly decreased the amount of PDGF receptor competing activity remaining in the supernatant. These results suggest that the factor produced by glioma cells has structural, immunological, and functional resemblance to PDGF. We previously reported that a human osteosarcoma cell line produces a PDGF-like molecule with growth-promoting activity. Taken together with the recent finding that PDGF is homologous to the transforming gene product of simian sarcoma virus, our present data give additional support for the idea that an autocrine activation of the PDGF receptor may be operational in the growth of human tumors of mesenchymal or glial origin.